arGEN-X SE ADR (ARGX): Price and Financial Metrics
ARGX Price/Volume Stats
| Current price | $580.59 | 52-week high | $678.21 |
| Prev. close | $573.51 | 52-week low | $368.57 |
| Day low | $573.58 | Volume | 243,600 |
| Day high | $584.76 | Avg. volume | 355,307 |
| 50-day MA | $586.86 | Dividend yield | N/A |
| 200-day MA | $591.20 | Market Cap | 35.45B |
ARGX Stock Price Chart Interactive Chart >
arGEN-X SE ADR (ARGX) Company Bio
argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced its 2021 corporate priorities and highlighted recent achievements from its late-stage immunology pipeline driven by its FcRn antagonist, efgartigimod. Additionally, the Company announced interim data from the Phase 2 CULMINATE trial of cusatuzumab in development with Cilag GmbH International, an affiliate of Janssen, and provided financial guidance for 2021. (Source:Wiki)
ARGX Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ARGX Price Returns
| 1-mo | -6.80% |
| 3-mo | -2.29% |
| 6-mo | -6.82% |
| 1-year | 50.10% |
| 3-year | 78.36% |
| 5-year | 156.96% |
| YTD | -5.60% |
| 2024 | 61.66% |
| 2023 | 0.42% |
| 2022 | 8.18% |
| 2021 | 19.08% |
| 2020 | 83.21% |